Active Biotech to Present at the Jefferies 2011 Global Healthcare Conference

Lund, Sweden, June 8, 2011 - Active Biotech (NASDAQ OMX NORDIC: ACTI) is
scheduled to present at the Jefferies 2011 Global Healthcare Conference held
June 6-9, 2011 at the Grand Hyatt New York, New York City, US. During the
presentation, an update regarding Active Biotech's development programs will be

The presentation will include projects in Phase III; laquinimod, a novel oral
immunomodulatory drug for the treatment of multiple sclerosis, licensed to Teva
Pharmaceutical Industries Ltd, the prostate cancer project TASQ, in co-
development with Ipsen as well as ANYARA, Active Biotech's novel concept for
tumor therapy in a Phase III study for renal cell cancer. Also, the project
57-57 and the pre-clinical ISI project will be presented.

The audio and slide presentation will be webcasted live and can be accessed via
the Active Biotech web site. To access the live and replay presentations please
go to -

The presentation will take place on June 8, at 2:00 pm US Eastern Daylight Time
/ 20.00 Central European Summer Time.

About Active Biotech
Active  Biotech AB  (NASDAQ OMX  NORDIC: ACTI)  is a  biotechnology company with
focus  on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are   laquinimod,   an   orally   administered   small   molecule   with  unique
immunomodulatory  properties for the  treatment of multiple  sclerosis, TASQ for
prostate  cancer and  ANYARA for  use in  cancer targeted  therapy, primarily of
renal  cell  cancer.  In  addition,  laquinimod  is  in Phase II development for
Crohn's  and Lupus.  Further projects  in clinical  development comprise the two
orally  administered compounds, 57- 57 for SLE and Systemic Sclerosis as well as
RhuDex(TM) for RA. Please visit www.activebiotech.comfor more information.

Active Biotech is required under the Securities Markets Act to make the
information in this press release public. The information was submitted for
publication at 08:30 am CEST on June 8, 2011.

Active Biotech AB
Göran Forsberg, VP Investor Relations & Business Development
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

Active Biotech to Present at the Jefferies 2011 Global Healthcare Conf:

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE